GUFICBIO427.80

Gufic Biosciences Limited

· Pharma & Health
₹ CrorePeersRPGLIFEUNICHEMLABGUJTHEMORCHPHARMASMSPHARMAINDSWFTLABFDCIOLCPMcap ₹4,290 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)214.39229.97278.45278.45
Receivable Days (DSO)149.29140.07114.99114.99
Payable Days (DPO)177.80168.34170.80164.00
Cash Conversion Cycle (days)185.88201.70222.64229.44
Working Capital Turnover3.533.463.323.45
Asset Turnover0.740.700.700.70
Cash Conversion (CFO/Net Income)-0.091.760.700.70
CFO/EBITDA-0.050.910.300.30
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.